Siafis, Spyridon
Fountoulakis, Konstantinos N.
Fragkidis, Vasileios
Papazisis, Georgios
Funding for this research was provided by:
Technische Universität München
Article History
Received: 3 November 2022
Accepted: 18 April 2023
First Online: 26 May 2023
Declarations
:
: The study was an analysis of anonymized data from the Greek nationwide prescription registry database. The Greek nationwide prescription registry database runs under surveillance of the Greek e-Government Center for Social Security Services (IDIKA S.A.) on behalf of the Greek Ministry of Health. The study was reviewed and approved on 21.09.2021 by the Data Protection Office of the Greek Ministry of Health. Therefore, access to the anonymized data was permitted by the Greek Ministry of Health and informed consent to participate was accordingly not applicable. All methods were carried in accordance with relevant guidelines and regulations in the Declaration of Helsinki, whenever applicable.
: Not applicable. Anonymized prescription data were requested and provided for this analysis by the Greek e-Government Center for Social Security Services (IDIKA S.A.) and the Greek Ministry of Health.
: KNF has received grants and served as consultant, advisor or CME speaker for the following entities: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Recordatti, Angellini, Pfizer, the Pfizer Foundation, Sanofi-Aventis, Servier, Shire and others. GP, VF and SS have none to declare.